NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 02/01/24

2024-02-01 12:36:09 ET More on Mid-day movers & stocks. Nextracker Inc. 2024 Q3 - Results - Earnings Call Presentation Nextracker Inc. (NXT) Q3 2024 Earnings Call Transcript Nextracker Inc.: Riding The Solar Power Tide While Growing Profitably Nextracker ...

NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is one today's most active stocks by volume. So far today, approximately 36,413 shares of NeuroBo Pharmaceuticals, Inc. have been exchanged, as compared to an average 30-day volume of 47,156 shares. NeuroBo Pharmaceuticals, Inc., a clinical-stage bi...

2024-02-01 10:00:10 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-02-01 09:38:18 ET More on NeuroBo Pharmaceuticals Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial information for NeuroBo Pharmaceuticals Read the full article on Seeking Alp...

2024-02-01 09:12:39 ET DENVER, Colo., Feb. 1, 2024 ( www.247marketnews.com )- NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) reported, this morning, that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomod...

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity PR Newswire Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Ti...

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of...

2024-01-09 08:58:01 ET More on NeuroBo Pharmaceuticals Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial information for NeuroBo Pharmaceuticals For further details see: NeuroBo P...

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement PR Newswire CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic d...

NeuroBo to Participate in Industry and Investor Conferences in January PR Newswire CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic dis...